Evaluation of antibiotic synergy against Acinetobacter baumannii:: a comparison with Etest, time-kill, and checkerboard methods

被引:109
作者
Bonapace, CR [1 ]
White, RL [1 ]
Friedrich, LV [1 ]
Bosso, JA [1 ]
机构
[1] Med Univ S Carolina, Coll Pharm, Anti Infect Res Lab, Charleston, SC 29425 USA
关键词
D O I
10.1016/S0732-8893(00)00163-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Acinetobacter baumannii is becoming increasingly resistant to antibiotics, often requiring combination therapy. Numerous methods exist to detect the presence of in vitro synergy with the time-kill and checkerboard tests being widely used. The Epsilometer test (E test) is a new method that is less labor intensive, but has not been evaluated using a wide range of antimicrobials and organisms. We assessed synergy using the time-kill and checkerboard tests and compared the results to the E test method using 10 clinical isolates of A. baumannii. Antimicrobial combinations evaluated consisted of trovafloxacin or tobramycin in combination with cefepime or piperacillin. Synergy was detected with all combinations by either the checkerboard or time-kill method. Synergy was not detected by the Etest method. The agreement between the time-kill test and Etest method was 72% (range 42-97%); for the time-kill and checkerboard tests, agreement was 51% (range 30-67%). The Etest method appears promising although further testing should be performed with additional antimicrobial agents and organisms. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 19 条
[1]   Worldwide emergence of carbapenem-resistant Acinetobacter spp. [J].
Afzal-Shah, M ;
Livermore, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (05) :576-577
[2]   Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies [J].
Bajaksouzian, S ;
Visalli, MA ;
Jacobs, MR ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1073-1076
[3]   EPIDEMIOLOGY OF NOSOCOMIAL INFECTIONS DUE TO ACINETOBACTER-CALCOACETICUS [J].
BERGOGNEBEREZIN, E ;
JOLYGUILLOU, ML ;
VIEU, JF .
JOURNAL OF HOSPITAL INFECTION, 1987, 10 (02) :105-113
[4]   HOSPITAL INFECTION WITH ACINETOBACTER SPP - AN INCREASING PROBLEM [J].
BERGOGNEBEREZIN, E ;
JOLYGUILLOU, ML .
JOURNAL OF HOSPITAL INFECTION, 1991, 18 :250-255
[5]   Acinetobacter spp, as nosocomial pathogens: Microbiological, clinical, and epidemiological features [J].
BergogneBerezin, E ;
Towner, KJ .
CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (02) :148-+
[6]   IDENTIFICATION AND BIOTYPING OF CLINICAL ISOLATES OF ACINETOBACTER [J].
BOUVET, PJM ;
GRIMONT, PAD .
ANNALES DE L INSTITUT PASTEUR-MICROBIOLOGIE, 1987, 138 (05) :569-578
[7]   Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa [J].
Cappelletty, DM ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :677-683
[8]   SYNERGISTIC INTERACTIONS OF CIPROFLOXACIN AND EXTENDED SPECTRUM BETA-LACTAMS OR AMINOGLYCOCIDES AGAINST ACINETOBACTER-CALCOACETICUS SS ANITRATUS [J].
CHOW, AW ;
WONG, J ;
BARTLETT, KH .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1988, 9 (04) :213-217
[9]  
Eliopolous GM., 1996, Antibiotics in laboratory medicine, P330
[10]  
GLEW RH, 1977, ANTIMICROB AGENTS CH, V6, P1036